

# The association between aging or chronic diseases and mitochondrial oxygenation and oxygen consumption as measured with the Protoporphyrin IX Triplet State Lifetime Technique

Published: 21-05-2021

Last updated: 30-01-2025

The primary objective of this study is to observe the association between age and mitoPO2 values. The secondary objective is to evaluate whether there is also an association between age and the mitoVO2 values. Further objectives are to investigate...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Completed
<b>Health condition type</b>	Other condition
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON51166

### Source

ToetsingOnline

### Brief title

Aging, chronic disease, mitoPO2 and mitoVO2

### Condition

- Other condition

### Synonym

aging, seniority

### Health condition

Veroudering

## Research involving

Human

## Sponsors and support

**Primary sponsor:** Anesthesiologie

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Aging, Chronic disease, Mitochondria, Oxygen

## Outcome measures

### Primary outcome

MitoPO<sub>2</sub> (mmHg). Ten mitoPO<sub>2</sub> (mmHg) baseline measurements will be performed on both the sternum and upper arm of all subjects. The mean and standard deviation of those measurements will compute the baseline mitoPO<sub>2</sub> for every participant.

### Secondary outcome

MitoVO<sub>2</sub> (mmHg/second). Applying pressure on the probe will cause a temporary halt of circulation to the mitochondria. As the oxygen consumption continues, this will result in a time-dependent decrease in mitoPO<sub>2</sub> from which the mitoVO<sub>2</sub> can be calculated in mmHg/second. Three mitoVO<sub>2</sub> measurements will be performed on both the sternum and the upper arm and the mean will be calculated for both.

## Study description

### Background summary

A new technique to measure mitochondrial oxygen tension was recently developed and calibrated by our lab. With this technique, mitochondrial oxygen tension \*mitoPO<sub>2</sub>\* and mitochondrial oxygen consumption \*mitoVO<sub>2</sub>\* can be measured in human skin. This led to the introduction of the COMET, an acronym of Cellular Oxygen METabolism (COMET, Photonics Healthcare B.V. Utrecht) which enables bed-side monitoring of mitoPO<sub>2</sub> and mitoVO<sub>2</sub> in real-time. Previous studies have

illustrated the potential of these measurements in various clinical conditions, unfortunately the influence of aging and chronic disease has not been examined. Before the COMET monitor can be used in clinical settings, it has to be known if these factors have any influence on the measurements. This study will therefore, examine the association between age and mitoPO2 and mitoVO2 values. Secondly, it will investigate whether there is any association between comorbidity and mitoPO2.mitoVO2. Lastly, the study will evaluate if mitoPO2 and mitoVO2 values differ between measurement location namely, the upper arm or sternum. This is because measurement locations vary in different clinical settings.

## **Study objective**

The primary objective of this study is to observe the association between age and mitoPO2 values. The secondary objective is to evaluate whether there is also an association between age and the mitoVO2 values. Further objectives are to investigate the association between diabetes, obesity and neurodegenerative diseases and mitoPO2 and mitoVO2 values. Lastly, the study will evaluate whether mitoPO2 and mitoVO2 values differ between measurements done on the upper arm or the sternum.

## **Study design**

Single center observational trial in healthy volunteers and patients with diabetes, obesity or neurodegenerative disease.

## **Study burden and risks**

The intracellular oxygen measurements is a non-invasive measurement technique. The specific discomfort for the subject is the aminolevulinic acid containing-plaster that makes the skin sensitive for light. This plaster is applied on the skin at least five hours before measurement. The participants will not benefit directly from participation of the study. It will cost the patients about an hour of extra time. Overall the risks are considered negligible and the burden low. The study will aid in the development of new techniques to improve therapy strategies for various diseases. Therefore the group related benefits outweigh the risks in this study.

## **Contacts**

### **Public**

Selecteer

Doctor Molewaterplein 40

Rotterdam 3015GD  
NL  
**Scientific**  
Selecteer

Doctor Molewaterplein 40  
Rotterdam 3015GD  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Healthy volunteers

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- Aged between 18 years of age and 90 years of age
- Acceptable proficiency of the Dutch language
- Healthy volunteers without physical or mental illness

Comorbidity group

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- Aged between 18 years of age and 90 years of age
- Acceptable proficiency of the Dutch language
- One of the underlying illnesses: neurodegenerative disease, diabetes mellitus type II or obesity (BMI>30), no other relevant comorbidity

### Exclusion criteria

A potential subject who meets any of the following criteria will be excluded

from participation in this study:

- Porphyria
- Known intolerance to components of the ALA plaster
- Presence of mitochondrial disease
- Pregnancy/lactation
- Patients with skin lesions on the measurement location which impede measurements
- Incapability to provide informed consent, due to a mental condition interfering with the ability to understand the provided information

## Study design

### Design

**Study type:** Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Completed

Start date (anticipated): 27-05-2021

Enrollment: 319

Type: Actual

### Medical products/devices used

Generic name: COMET

Registration: Yes - CE intended use

## Ethics review

Approved WMO

Date: 21-05-2021

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

ID: 25614

Source: NTR

Title:

### In other registers

Register	ID
CCMO	NL76685.078.21